|
|
Geovax Labs Inc (NASDAQ: GOVX) |
|
Price: $0.6324
$-0.09 
-12.288%
|
| Day's High:
| $0.6789000034332275
| Week Perf:
| -1.5 %
|
| Day's Low: |
$ 0.59 |
30 Day Perf: |
-7.14 % |
| Volume (M): |
625,152 |
52 Wk High: |
$ 19.20 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$5.32 |
| Open: |
$0.66 |
52 Wk Low: |
$0.59 |
|
|
| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
5 |
| Employees |
19 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-20 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
GeoVax Labs Inc. is a biotechnology company that focuses on developing innovative vaccines to prevent and treat infectious diseases, including HIV/AIDS. The company utilizes a unique vaccine platform called Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) to design and develop its vaccines. This platform allows for the production of non-infectious virus-like particles that mimic the target virus, triggering an immune response to provide protection against the actual virus.
GeoVax Labs' vaccines are designed to be safe, effective, and easy to produce, making them suitable for large-scale distribution. The company has dedicated significant efforts into developing an effective HIV/AIDS vaccine that can provide a durable and long-lasting immune response. Additionally, GeoVax Labs is exploring opportunities to apply its MVA-VLP platform for the development of vaccines against other infectious diseases, such as Zika, Ebola, and Lassa fever.
With a team of experienced scientists and researchers, GeoVax Labs is committed to advancing the field of vaccine development and public health. The company collaborates with various research institutions, government agencies, and pharmaceutical companies to accelerate the progress of its vaccine programs. By addressing global health challenges, GeoVax Labs strives to make a positive impact on the lives of millions of individuals worldwide.
Company Address: 1955 Lake Park Drive, Suite 300 Smyrna 30080 GA
Company Phone Number: 384-7220 Stock Exchange / Ticker: NASDAQ GOVX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Financing Agreement
Published Tue, Aug 20 2024 11:45 AM UTC
GeoVax Labs: A Bold Move in Biotechnology Secures $8.5 Million to Advance Cancer and Infectious Disease Therapies
In a significant development for its growth and future initiatives, GeoVax Labs, Inc. (Nasdaq: GOVX), an Atlanta-based biotechnology company focused on immunotherapy and vaccine development, has announced a strategic fundraising effort aimed at rai...
|
| Announcement
Published Thu, Aug 8 2024 1:00 PM UTC
Strategic Enhancements in Vaccine Development: GeoVax Strengthens Scientific Advisory Board with Appointment of Teresa Lambe, Acclaimed Oxford Vaccine ExpertIn a significant advancement for its scientific leadership, GeoVax Labs, Inc., a biotechnology firm focused on the development of innovative vaccine solutions, has appointed Teresa Lambe, an acclaimed professor of vacci...
|
| Clinical Study
Published Wed, Jul 31 2024 1:00 PM UTC
GeoVax Advances Gedeptin Cancer Therapy into Phase 2 Trials, Focusing on Head and Neck Cancer In a significant move for cancer therapeutics, GeoVax Labs, Inc. has unveiled plans to initiate Phase 2 clinical trials for its innovative Gedeptin cancer therapy. This decision follows a thorough review by the company s Clinical Advisory Committee, which has expressed strong suppo...
|
| Stocks on the Move
Published Fri, Jul 12 2024 6:13 PM UTC
:This article reviews recent developments and market trends related to GeoVax Labs Inc., a clinical-stage biotechnology company that specializes in the development of immunotherapies and vaccines targeting cancer and infectious diseases. Over the past month, GeoVax has garnered significant attention from market experts and analysts, with an increased price target, reiterated...
|
| Stocks on the Move
Published Tue, Jul 2 2024 2:41 PM UTC
Geovax Labs Inc, a biotechnology company focusing on the development of immunotherapies and vaccines targeting cancers and infectious diseases, has seen a decline in its share performance in recent weeks. This decline can be attributed to several factors, including a change in the company s price target, insider transactions, and the initiation of a new clinical study, among...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-8.51 $ |
| Revenues (TTM) |
0 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.69 $
|
| Book Value |
0.39 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
- |
| Net
Income per Employee (TTM) |
-1,075,044 |
| Receivable Turnover Ratio (TTM) |
- |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
- |
|
|
| Per Share |
|
| Earnings (TTM) |
-8.51 $
|
| Revenues (TTM) |
0 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.69 $
|
| Book Value |
0.39 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
55.41% 